Antibodies

2 June 2008

Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy

2 June 2008

Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate

2 June 2008

CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma

30 May 2008

Merck Receives CHMP Positive Opinion for Marketing Authorization for Erbitux Including First-Line Colorectal Cancer in the European Union

30 May 2008

Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer

30 May 2008

Genmab initiates Zalutumunab combination study in Colorectal Cancer

28 May 2008

Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))

28 May 2008

Ablynx Announces Initiation of a Phase Ib Study in Patients for ALX-0081 and Provides a Business Update for the First Quarter 2008

21 May 2008

Cimzia(R) provides long-term efficacy with stable dosing in Crohn’s disease

21 May 2008

Medarex Reports Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week

21 May 2008

Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology

20 May 2008

Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study

20 May 2008

Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient Enrollment

19 May 2008

Patient recruitment started in Phase III registration trial with CA9-SCAN

19 May 2008

Schering-Plough Extends Antibody Alliance with MorphoSys

16 May 2008

ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting

15 May 2008

Lpath’s iSONEP(TM) IND Application Gets Green Light From FDA

13 May 2008

Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment

13 May 2008

Affimed validates antibody target for cancer metastasis

13 May 2008

Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines

13 May 2008

Active Biotech advances ANYARA into Phase III clinical trial

12 May 2008

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

9 May 2008

Actemra inhibits joint damage and improves physical function of patients with Rheumatoid Arthritis

8 May 2008

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

8 May 2008

Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis

30 April 2008

Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis

29 April 2008

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial

29 April 2008

Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus

28 April 2008

MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 Program

28 April 2008

Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD40 Agonists & CD40/L Antagonists Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Adalimumab (Humira) Biosimilars Pipeline Review